Advertisement

Erythroderma

  • Katrina Harper-Kirksey
Chapter

Abstract

Erythroderma, often described as generalized exfoliative dermatitis, is a condition in which erythema involves greater than 90% of the body surface, often as a result of an underlying inflammatory skin condition, which can result in a variety of systemic manifestations and potentially lead to life-threatening complications.

Keywords

Erythema Scaling Exfoliation Hypersensitivity Vasodilation Edema Systemic Drug reaction 

References

  1. 1.
    Khaled A, Sellami A, Fazaa B, Kharfi M, Zeglaoui F, Kamoun MR. Acquired erythroderma in adults: a clinical and prognostic study. J Eur Acad Dermatol Venereol. 2010;24:781–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Usatine RP, Smith MA, Chumley HS, Mayeaux EJ Jr. Erythroderma. In: Usatine RP, Smith MA, Chumley HS, Mayeaux Jr EJ, editors. The color atlas of family medicine. 2nd ed. New York: McGraw-Hill; 2013.Google Scholar
  3. 3.
    Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the “red man”. Clin Dermatol. 2005;23:206–17.CrossRefPubMedGoogle Scholar
  4. 4.
    Pal S, Haroon TS. Erythroderma: a clinico-etiologic study of 90 cases. Int J Dermatol. 1998;37:104.CrossRefPubMedGoogle Scholar
  5. 5.
    Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: a clinical study of 97 cases. BMC Dermatol. 2005;5:5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rym BM, Mourad M, Bechir Z, et al. Erythroderma in adults: a report of 80 cases. Int J Dermatol. 2005;44:731.CrossRefPubMedGoogle Scholar
  7. 7.
    Grant-Kels JM, Fedeles F, Rothe MJ. Exfoliative dermatitis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw Hill Medical; 2012.Google Scholar
  8. 8.
    Sheen YS, Chu CY, Wang SH, Tsai TF. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. J Dermatol Treat. 2009;20:340.CrossRefGoogle Scholar
  9. 9.
    Li J, Zheng HY. Erythroderma: a clinical and prognostic study. Dermatology. 2012;225:154–62.CrossRefPubMedGoogle Scholar
  10. 10.
    Sigurdsson V, Toonstra J, van Vloten WA. Idiopathic erythroderma: a follow-up study of 28 patients. Dermatology. 1997;194:98.CrossRefPubMedGoogle Scholar
  11. 11.
    Thestrup-Pedersen K, Halkier-Sørensen L, Søgaard H, Zachariae H. The red man syndrome. Exfoliative dermatitis of unknown etiology: a description and follow-up of 38 patients. J Am Acad Dermatol. 1988;18:1307.CrossRefPubMedGoogle Scholar
  12. 12.
    Kanthraj GR, Srinivas CR, Devi PU, et al. Quantitative estimation and recommendations for supplementation of protein lost through scaling in exfoliative dermatitis. Int J Dermatol. 1999;38:91.CrossRefPubMedGoogle Scholar
  13. 13.
    Sigurdsson V, Steegmans PH, van Vloten WA. The incidence of erythroderma: a survey among all dermatologists in the Netherlands. J Am Acad Dermatol. 2001;45:675.CrossRefPubMedGoogle Scholar
  14. 14.
    Sarkar R, Garg VK. Erythroderma in children. Indian J Dermatol Venereol Leprol. 2010;76:341. Sarkar R, Basu S, Sharma RC. Neonatal and infantile erythrodermas. Arch Dermatol. 2001;137:822CrossRefPubMedGoogle Scholar
  15. 15.
    Fraitag S, Bodemer C. Neonatal erythroderma. Curr Opin Pediatr. 2010;22(4):438–44.CrossRefPubMedGoogle Scholar
  16. 16.
    Sigurdsson V, Toonstra J, Hezemans-Boer M, van Vloten WA. Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol. 1996;35:53.CrossRefPubMedGoogle Scholar
  17. 17.
    Sehgal VN, Srivastava G, Sardana K. Erythroderma/exfoliative dermatitis: a synopsis. Int J Dermatol. 2004;43:39–47.CrossRefPubMedGoogle Scholar
  18. 18.
    Sterry W, Steinhoff M. Erythroderma. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology.3rd ed. Philadelphia: Elsevier Saunders; 2012:171–181.Google Scholar
  19. 19.
    Bi MY, Curry JL, Christiano AM, et al. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 2011;64:53.CrossRefPubMedGoogle Scholar
  20. 20.
    Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol. 2010;11:157.CrossRefPubMedGoogle Scholar
  21. 21.
    Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–62.CrossRefPubMedGoogle Scholar
  22. 22.
    Mistry N, Gupta A, Alva A, Sibbald G. A review of the diagnosis and Management of Erythroderma (generalized red skin). In: Advances in skin and wound care: Woltkers Kluwer Health; 2015. p. 228–36. www.woundcarejournal.com.
  23. 23.
    Yuan XY, Guo JY, Dang YP, Qiao L, Liu W. Erythroderma: a clinical-etiological study of 82 cases. Eur J Dermatol. 2010;20(3):373–7.PubMedGoogle Scholar
  24. 24.
    Lancrajan C, Bumbacea R, Giurcaneanu C. Erythrodermic atopic dermatitis with late onset casepresentation. J Med Life. 2010;3:80–3.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Botella-Estrada R, Sanmartin O, Oliver V, Febrer I, Aliaga A. Erythroderma. A clinicopathological study of 56 cases. Arch Dermatol. 1994;130:1503–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol. 1980;5:105. PMID7398119CrossRefPubMedGoogle Scholar
  27. 27.
    Megna M, Sidikov AA, Zaslavsky DV, Chuprov IN, Timoshchuk EA, Egorova U, et al. The role of histological presentation in erythroderma. Int J Dermatol. 2017;56(4):400–4.CrossRefPubMedGoogle Scholar
  28. 28.
    Ram-Wolff C, Martin-Garcia N, Bensussan A, Bagot M, Ortonne N. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies. Am J Dermatopathol. 2010;32(8):755–63.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zip C, Murray S, Walsh NM. The specificity of histopathology in erythroderma. J Cutan Pathol. 1993;20:393.CrossRefPubMedGoogle Scholar
  30. 30.
    Vasconcellos C, Domingues PP, Aoki V, et al. Erythroderma: analysis of 247 cases. Rev Saude Publica. 1995;29:177.CrossRefPubMedGoogle Scholar
  31. 31.
    Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(4):432–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Bruno TF, Grewal P. Erythroderma: a dermatologic emergency. CJEM. 2009;11(3):244–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013;13(4):549–61.CrossRefPubMedGoogle Scholar
  34. 34.
    Shimizu H. Shimizu’s textbook of dermatology. 1st ed. Tokyo: Hokkaido University Press/Nakayama Shoten; 2007. p. 122–5.Google Scholar
  35. 35.
    Katsarou A, Armenaka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011;25(1):12–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Gelbard CM, Hebert AA. New and emerging trends in the treatment of atopic dermatitis. Patient Prefer Adherence. 2008;2:387–92.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol. 2004;140:366.CrossRefPubMedGoogle Scholar
  38. 38.
    Barland C, Kerdel FA. Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis. Arch Dermatol. 2003;139:949–50.CrossRefPubMedGoogle Scholar
  39. 39.
    Ladizinski B, Lee KC, Wilmer E, Alavi A, Mistry N, Sibbald RG. A review of the clinical variants and the management of psoriasis. Adv Skin Wound Care. 2013;26:271–84.CrossRefPubMedGoogle Scholar
  40. 40.
    Zattra E, Belloni Fortina A, Peserico A. Alaibac M. Erythroderma in the era of biological therapies. Eur J Dermatol. 2012;22(2):167–71.PubMedGoogle Scholar
  41. 41.
    Rupoli S, Canafoglia L, Goteri G, Leoni P, Brandozzi G, Federici I, et al. Results of a prospective phase II trial with oral low dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides. Eur J Dermatol. 2016;26(1):13–20.Google Scholar
  42. 42.
    Sokolowska-Wojdylo M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, et al. Polish lymphoma research group experience with bexarotene in the treatment of cutaneous T-cell lymphoma. Am J Ther. 2016;23(3):e749–56.Google Scholar
  43. 43.
    Chung CG, Poligone B. Cutaneous T cell lymphoma: an update on pathogenesis and systemic therapy. Curr Hematol Malig Rep. 2015;10(4):468–76.CrossRefPubMedGoogle Scholar
  44. 44.
    Galper SL, Smith BD, Wilson LD. Diagnosis and management of mycosis fungoides. Oncology (Williston Park). 2010;24(6):491–501.Google Scholar
  45. 45.
    Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151–65.CrossRefPubMedGoogle Scholar
  46. 46.
    Al Hothali GI. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. Int J Health Sci (Qassim). 2013;7(2):220–39.CrossRefGoogle Scholar
  47. 47.
    Leger M, Newlove T, Robinson M, Patel R, Meehan S, Ramachandran S. Pityriasis rubra pilaris. Dermatol Online J. 2012;18(12):14.PubMedGoogle Scholar
  48. 48.
    Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21:985.CrossRefPubMedGoogle Scholar
  49. 49.
    Kubica AW, Davis MD, Weaver AL, et al. Sézary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol. 2012;67:1189.CrossRefPubMedGoogle Scholar
  50. 50.
    Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol. 1995;131:1003.CrossRefPubMedGoogle Scholar
  51. 51.
    Wang J, Wang YM, Ahn HY. Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications. AAPS J. 2014;16(5):938–47.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Cather JC, Crowley JJ. Use of biologic agents in combination with other therapies for the treatment of psoriasis. Am J Clin Dermatol. 2014;15(6):467–78.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Zattra E, Belloni Fortina A, Peserico A. Alaibac M. Erythroderma in the era of biological therapies. Eur J Dermatol. 2012;22(2):167–71.PubMedGoogle Scholar
  54. 54.
    Umar, S, Kelly P. Erythroderma (Generalized Exfoliative Dermatitis) clinical presentation. Medscape. (updated June 4 2018). Retrieved 2018 from https://emedicine.medscape.com/article/1106906-overview.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Emergency Medicine, Department of Anesthesia Critical CareNYU Langone Medical CentersNew YorkUSA

Personalised recommendations